143 related articles for article (PubMed ID: 22424710)
1. Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin's lymphoma cells.
Kewitz S; Bernig T; Staege MS
Leuk Res; 2012 Jun; 36(6):773-8. PubMed ID: 22424710
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs.
Staege MS; Banning-Eichenseer U; Weissflog G; Volkmer I; Burdach S; Richter G; Mauz-Körholz C; Föll J; Körholz D
Exp Hematol; 2008 Jul; 36(7):886-96. PubMed ID: 18400362
[TBL] [Abstract][Full Text] [Related]
5. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.
Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR
Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977
[TBL] [Abstract][Full Text] [Related]
6. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of class I and II vs class III histone deacetylase inhibitors in neuroblastoma.
Lautz TB; Naiditch JA; Clark S; Chu F; Madonna MB
J Pediatr Surg; 2012 Jun; 47(6):1267-71. PubMed ID: 22703804
[TBL] [Abstract][Full Text] [Related]
8. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
9. Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells.
Ma YY; Lin H; Moh JS; Chen KD; Wang IW; Ou YC; You YS; Lung CC
Taiwan J Obstet Gynecol; 2011 Jun; 50(2):165-71. PubMed ID: 21791302
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
[TBL] [Abstract][Full Text] [Related]
11. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
12. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
Shi W; Han X; Yao J; Yang J; Shi Y
Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
[TBL] [Abstract][Full Text] [Related]
14. Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.
Fang Y; Hu Y; Wu P; Wang B; Tian Y; Xia X; Zhang Q; Chen T; Jiang X; Ma Q; Xu G; Wang S; Zhou J; Ma D; Meng L
Cancer Invest; 2011 May; 29(4):247-52. PubMed ID: 21345073
[TBL] [Abstract][Full Text] [Related]
15. Glutathione-S-transferases and Chemotherapy Resistance of Hodgkin's Lymphoma Cell Lines.
Bernig T; Ritz S; Brodt G; Volkmer I; Staege MS
Anticancer Res; 2016 Aug; 36(8):3905-15. PubMed ID: 27466493
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
17. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Chang H; Jeung HC; Jung JJ; Kim TS; Rha SY; Chung HC
Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
[TBL] [Abstract][Full Text] [Related]
18. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells.
Hirsch B; Hummel M; Bentink S; Fouladi F; Spang R; Zollinger R; Stein H; Dürkop H
Am J Pathol; 2008 Feb; 172(2):510-20. PubMed ID: 18187570
[TBL] [Abstract][Full Text] [Related]
19. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A
Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266
[TBL] [Abstract][Full Text] [Related]
20. Active extracts of wild fruiting bodies of Antrodia camphorata (EEAC) induce leukemia HL 60 cells apoptosis partially through histone hypoacetylation and synergistically promote anticancer effect of trichostatin A.
Lu MC; Du YC; Chuu JJ; Hwang SL; Hsieh PC; Hung CS; Chang FR; Wu YC
Arch Toxicol; 2009 Feb; 83(2):121-9. PubMed ID: 18709356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
